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Epidemiological studies have shown that approximately 50% of cancer 
incidence, and 30-35% of the cancer related mortality in Americans is 
associated with lifestyle habits, such as diet, tobacco and alcohol use. There 
is a direct relationship between diets rich in fruit and vegetables and a lower 
incidence o f cancer. Polyphenols and flavonoids froin green tea and soy 
have been extensively studied for their chemopreventive properties. 
However, cereal grains and legumes have not been well characterized even 
though they are a main component of the diet.
The objective of this study is to determine the possible chemopreventive 
properties of flavonoids and other polyphenols in cereal grains and legumes. 
Our approach towards chemoprevention is the inhibition of the carcinogenic 
process at the initiation step, by inducing Phase II enzymes, such as 
NADP(H): quinone oxidoreductase (NQOl), and at the promotion and 
progression step, by inhibiting cyclooxygenase-2 (COX-2).
In the present study, Hepalclc? (murine hepatoma) cells were exposed for 
48h to flavonoid extracts from cereal grains and legumes to evaluate their 
effect on NQOl activity. Preliminary studies showed significant induction 
rates with most of the extracts. Experiments conducted with a different set of 
extracts showed a significant NQOl induction with spring red wheat (1.5), 
winter wheat (1.6), wild rice (1.5), and lentil (1.8) extracts. Western blots 
were performed to assay COX-2 expression. Oats and rye flavonoids 
inhibited COX-2 expression in preliminary studies, after a 48 h exposure to 
U87 (human glioblastoma) cells. Studies with a second set of extracts failed 
to confirm these results. Further research is needed to evaluate dosage and 
toxicity. Collection of different fractions of the extractions should also be 
considered.
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Abbreviations
AA: arachidonic acid
aFGF: acidic fibroblast growth factor
Ah: aromatic hydrocarbon
A PI: activator protein-1
ARE: antioxidant-responsive element
bFGF: basic fibroblast growth factor
BHA: 2(3)-tert-butyl-4-hydroxyanisole
BHT: 3,5-di-tert-butyl-4-hydroxytoluene
COX: cyclooxygenase
DCPIP: 2, 6-dichlorophenolindophenol
ER: endoplasmic reticulum
ERK: extra cellular signal-regulated kinase
FAP: familial adenomatous polyposis
GST: glutathione-S-transferase
HRP: horseradish peroxidase
I3C: indole-3-carbinol
LPS: lipopolysaccharide
MAPK: mitogen-activated protein kinase
N Q O l: NAD(P)H: quinone reductase
NSAIDs: non-steroidal anti-inflammatory drugs
PG: prostaglandin
PGHS: prostaglandin endoperoxide H synthase 
ROS: reactive oxygen species 
XX: thromboxane
UDP-GT: UDP-glucuronyltransferases 
VEFG: vascular endothelial growth factor 
XRE: xenobiotic-responsive element
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INTRODUCTION
Cancer chemoprevention:
In Western societies cancer is one of the main causes of premature mortality, 
along with stroke and cardiovascular disease. The American Cancer Society estimates 
that 552,000 Americans died of cancer in the year 2000, and 1,220,100 new cancer cases 
were diagnosed (1). Epidemiological studies showed that nutrition and lifestyle factors, 
such as tobacco and excessive alcohol use account for approximately 50% of the cancer 
incidence and for 30-35% of the cancer related mortality (2). Although inherited genes 
influence the risk of developing cancer, genetic predisposition only explains a small 
portion of the total cancer cases. Cancer is a partially preventable disease and dietary and 
lifestyle choices can help to decrease the risk of cancer (1).
Cancer chemoprevention is the use of natural or synthetic compounds to block the 
development and progression of invasive neoplasia (3), Carcinogenesis is a multistep 
process that involves many biological alterations that can result in structural and 
functional changes in the genome. Carcinogenesis can be divided into three stages: 
initiation, promotion and progression. At initiation, a carcinogen interacts with DNA and 
causes simple mutations in the genome. DNA repair or metabolism of the initiating 
agents can alter the process of initiation, but if not repaired, it is considered an 
irreversible process because the genotype and / or the phenotype of the cells are 
established at this point. Initiated cells proliferate during promotion. Promotion is a 
reversible phase that occurs over a long period of time. Promoting agents alter gene 
expression through perturbation of signal transduction pathways, but they do not cause a 
direct alteration in DNA. Promoting agents can stimulate cell replication and inhibit
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apoptosis. Although the exact mechanisms are unknown, the mitogen-activated protein 
kinases (MAPKs) pathway and the phosphorylation of cyclins may be involved. 
Progression is the phase where pre-malignant neoplasia is transformed into invasive 
cancer. The progression step of carcinogenesis is characterized by karyotypic instability, 
irreversible genetic alterations, and cell selection for optimal neoplastic growth (4) 
(reviewed in (5)).
Cancer preventive agents can be categorized in two main classes as blocking 
agents and as suppressing agents. Blocking agents act at the initiation step of 
carcinogenesis by preventing carcinogens to reach cellular targets. Some blocking agents 
prevent the metabolic activation of certain carcinogens. Others stimulate detoxification 
enzymes to metabolize carcinogens before they can reach their target sites. Suppressing 
agents act at the promotion and progression step of carcinogenesis. They prevent the 
evolution from pre-neoplastic cells to malignant cells (6 ,7 ). Cancer preventive measures 
can be directed to high-risk groups or to the general population. For long-term assessment 
of populations at normal risk, the chemopreventive agents must be minimally toxic or 
nontoxic compounds. Dietary constituents are relatively safe and they are not perceived 
as medicine, which makes them the ideal candidates for this purpose. For the treatment of 
high-risk patients, those with genetic predisposition for certain cancers, previous cancer 
diagnosis or high exposure to a known carcinogen, compounds with a relative toxicity 
may be accepted (5,8).
Nutrient imbalances are one of the main ways in which diet contributes to cancer 
development. These imbalances are reflected in western diets, which have a deficiency of 
fiber and excess of fat intake (2). Numerous epidemiological studies have shown that
dietary fiber and whole grains are related to lower incidences of certain cancers, such as 
gastric and colon cancer (9-11). In addition to the epidemiological data, animal studies 
showed a beneficial effect of fiber, especially wheat bran fiber, in colon and breast cancer 
(12,13). The ideal fiber intake is 25-35 g/day in adults. Fifty percent of the total fiber 
intake should come from grains, 30% from vegetables and legumes, and about 20% from 
fruits (reviewed in (2)). One of the major nutritional excesses is the elevated proportion 
of calories of fat origin. In the United States fat intake accounts for 35% of the total 
calories, of which approximately 25% are saturated fatty acids. There is an association 
between high fat diets and elevated risk of developing colon cancer, breast cancer, 
prostate cancer, and lung cancer (reviewed in (2 )).
As mentioned earlier, whole grains may have protective properties against certain 
types of cancer. Whole grains can be classified as major cereal grains including rice, 
wheat and com, or as minor grains including barley, rye, oats, triticale, millet and 
sorghum (14). Wheat production constitutes one third of the total grain production and 
rice accounts for one fourth of the world production. Most grains are rich in fiber, starch, 
vitamins and minerals. They are low in fat and contain about 10-15 % protein. During 
milling, the bran and the germ are removed from the endosperm, which is then 
transformed into flour. In most refining processes, nutrients and phytochemicals present 
in high concentrations in the outer part of the grain are lost, reducing the nutritional value 
of the grain products (reviewed in (10)). Although most of their beneficial effects are 
related to their high content in fiber, other components such as antioxidants, 
phytoestrogens, phenolic compounds and trace elements may also play an important role 
in cancer prevention (10,15). Whole grains contain significant amounts of phenolic
acids, mainly in the bran layer. In wheat bran, the principal phenolic acid is ferrulic acid 
(10). Caffeic and ferrulic acid prevent carcinogen activation and their reaction with 
cellular targets (7). Phenols extracted from the bran layer of brown rice inhibited cell 
proliferation and decreased clonogenicity in breast and colon cells (16). The potential 
cancer protective effect of phenolic compounds may be related to their ability to 
stimulate detoxification enzymes, to inhibit arachidonic acid metabolism and possibly, to 
their ability for chelating iron (10,15). Other antioxidants present in whole grains are 
phytic acid, vitamin E and selenium. Phytic acid may be involved in the reduction of free 
radical production in the intestine by diminishing the amount of iron available for the 
Fenton reaction (15). Vitamin B is a fat-soluble vitamin that acts as a free radical 
scavenger. It has the potential to prevent the activation of carcinogens and to protect 
against oxidative damage in cellular membranes (6 ,10). Selenium acts as a cofactor for 
glutathione peroxidase, an enzyme that catabolizes peroxides and prevents the formation 
of free radicals, protecting tissues from oxidative damage (reviewed in (3,10)).
Along with cereal grains, legumes have been hypothesized as possible cancer 
chemopreventive agents. Legumes are the fruits or pods of a leguminous plant, such as 
beans, lentils and peas. Epidemiological studies have been inconclusive to show a 
protective effect against cancer with legumes (reviewed in (9)).
A variety of epidemiological studies have also shown a relationship between 
individuals who consume diets rich in fruit and vegetables and a lower incidence of 
cancer (17). Several nutrients found in these foods have shown cancer preventive 
properties by inhibiting mutagenesis and cell proliferation, as well as by inducing 
apoptosis (reviewed in (3)). There is evidence of chemopreventive properties from
indole-3-carbinol derivatives in cruciferous vegetables, organosulfur compounds from 
garlic, isoflavones from soy such as genistein, and polyphenolics from green tea 
(reviewed in (18)). Polyphenolics present in fruits and vegetables are major contributors 
to their antioxidant properties. The polyphenolic group can be divided into 
hydroxybenzoic acids (e.g. gallic and ellagic acids), hydroxycinnamic acids (e.g. ferrulic 
and cafeic acids), flavonoids and hydroxystilbenes (e.g. resveratrol) (19). Flavonoids 
(Figure 1) can be glycosylated, methylated or they can appear as aglycones. Flavonoids 
are derived from a benzo-y-pyrone structure, with a benzene derivative in position 2 
(flavonoids) or 3 (isoflavonoids). The ring attached to the benzene is a y-pyrone in 
flavonols and flavones and a dyhydro-derivative in flavanols and flavanones. Flavonols 
and flavones differ in the C2-C3 double bond and in the hydroxyl group in position 3. 
Anthocyanidines are compounds chemically and biologically related to flavonoids. They 
present an open C ring (20). Flavanols are present primarily in seeds and stems whereas 
flavonols and anthocyanidines are located in the skin of fruits (19). There is evidence in 
the literature of flavonoid content in different cereal grains, such as wheat, barley, and 
rice ((21), (22), reviewed in (23)), Flavonoids from barley, such as (+) catechin, (-) 
epicatechin and polymers of (+) catechin and (+) gallocatechin, showed antioxidant 
activity in vitro ((22)). There is also evidence of flavonoid content in legumes, such as 
soybeans, green and yellow beans. Condensed tannins are phenolic polymers that can 
also be found in grains and legumes (reviewed in (24)).
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Detoxification enzymes and cancer chemoprevention:
Tumor initiation can result from DNA damage by electrophilic compounds or by 
free radicals generated from the metabolism of carcinogens. In response to this damage, 
animal cells have evolved mechanisms for protection against toxic compounds (25). One 
of the principal mechanisms for cellular protection is the elevation of certain Phase II 
enzymes, such as giutathione-S-transferase (GST), NAD(P)H: quinone reductase (NQOl) 
and UDP-glucuronosyltransferases (UDP-GT) as well as elevated levels of glutathione 
(25).
Biotransformation enzymes can be divided into two groups. Phase I and Phase II. 
Phase I enzymes include the cytochrome P450 group, cyclooxygenases, and monoamine 
reductases. Examples of Phase II detoxification enzymes include the quinone reductases, 
UDP-GTs, and GSTs. Phase I enzymes are involved in reactions that generate 
electrophilic species. On the contrary, Phase II enzymes either inhibit the formation of 
electrophiles or catalyze their conversion to inactive and more water-soluble conjugates. 
This enables them to be rapidly excreted from the body. The balance between Phase I and 
Phase II enzymes contributes to the risk of chemically induced cancer of an individual 
(reviewed in (26)).
Phase II enzymes can be regulated / stimulated by monofunctional or bifunctional 
inducers. Monofunctional inducers cause an electrophilic response in the cell that 
stimulates the transcription of Phase II enzymes. This type of induction involves binding 
to the activator protein-1 (API) site in the antioxidant-responsive element (ARE). 
Bifunctional inducers bind the aromatic hydrocarbon (Ah) receptor, forming an 
inducer/Ah receptor complex which binds to the xenobiotic-responsive element (XRE),
stimulating the transcription of both Phase I and Phase II enzymes (26-28). Induction of 
Phase I enzymes could potentially lead to the activation of some carcinogens. Therefore, 
the ideal chemopreventive agent is a nontoxic compound that stimulates Phase II 
enzymes without inducing Phase I enzymes (26).
The flavoprotein N Q O l [NAD(P)H: quinone oxidoreductase; EC 1.6.99.2] or DT- 
diaphorase is a two-electron quinone reductase that uses NADH or NADPH as reducing 
cofactors. NQ O l (Figure 2) reduces quinones directly to hydroquinones. This bypasses 
potentially toxic semiquinones, avoiding the formation of free radicals generated in redox 
cycling. Hydroquinones can then be conjugated and excreted from the body (27, 29, 30).
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F igure 2. Quinone metabolism by NQOl (27).
N QOl is a homodimeric flavoprotein, containing one FAD molecule in each 
subunit. Crystal structure studies reveal the existence of two polypeptide chains that 
dimerize to form two identical catalytic sites (reviewed in (31)). These observations
support a ping-pong mechanism for the reduction of xenobiotics such as quinones by 
N Q O l. In this reaction, a hydride is transferred from NAD(P)H to FAD and from 
FADH2 to the quinone substrate. This explains the mandatory two-electron reduction of 
the quinones by NQ O l (reviewed in (32)), In humans, N Q O l is mainly distributed 
among tissues that need high antioxidant protection. These tissues include the vascular 
endothelium, epithelial cells of the breast, lung and colon, adipocytes, epithelium of 
cornea, lens and retina, and optic nerve (reviewed in (31)). At the cellular level, 90% of 
the enzyme is found in the cytosol and in smaller amounts associated with the 
mitochondria and microsomes (reviewed in (29)).
Induction of Phase II detoxification enzymes by natural or synthetic compounds is 
a well-established strategy towards cancer chemoprevention (25,26, 33-35). It has been 
shown that NQOl induction protects against toxicity, mutagenesis or carcinogenesis (33, 
35-37). A wide variety of chemically diverse compounds such as phenolic antioxidants, 
polycyclic aromatic hydrocarbons, azo dyes, flavonoids, coumarin and certain sulfur 
compounds induced NQOl in H epalclc? murine hepatoma cells (38) and showed 
chemoprotective effects in vivo (7). Certain antioxidants such as BHA [2(3)-tert-butyl-4- 
hydroxyanisole], BHT (3,5-di-tert-butyl-4-hydroxytoluene), ethoxyquin (l,2-dihydro-6- 
ethoxy-2, 2,4-trimethylquinoline), and disulfiram [bis(diethylthiocarbamyl)disulfide] 
stimulated NQOl and protected against polycyclic aromatic hydrocarbon-induced cancer 
(reviewed in (36)). The protective effects of these antioxidants were associated with their 
ability to stimulate NQOl and other detoxification enzymes. Induction of such enzymes 
results in the inactivation of electrophiles, and as a consequence, in protection against 
free radical damage (36, 39-41).
Diets rich in fruits, vegetables, whole grains and legumes have been associated 
with a decreased cancer risk. High phytoestrogens concentrations contained in those diets 
are believed to be in part responsible for the protective effect. Dietary phytoestrogens 
such as genistein, enterolactone, biochanin A and coumestrol increased N Q O l expression 
in colonic Colo205 cells after a 48-hour exposure to different concentrations (0.001 to 
lO.OpM) of the compounds. The highest increase in the expression (6  to 8 -fold) was 
observed with enterolactone and genistein. These two compounds doubled NQOl activity 
at concentrations of 0.14 and 0.04 pM, respectively, followed by biochanin A (1.1 pM) 
and coumestrol (12.0 pM) (42). There is also evidence of the correlation between the 
ability of coumarin and 4 ’-bromoflavone to induce NQOl and their protection against 
chemically induced cancer (43,44). Quercetin is one of the most prevalent flavonoids in 
the diet. It has cytoprotective and anti-tumorigenic properties as shown in different 
animal studies, where quercetin inhibited colon, skin and mammary tumors (4 5 ). 
Exposure of quercetin (15pM) to a human breast carcinoma cell line (MCF-7) for a 
period of 24 h resulted in a two-fold increase in NQOl activity and a three- to four-fold 
increase in NQOl gene expression (46).
Flavonoids from onions induced NQOl after a 24-hour exposure in H epalclc? 
cells. Quercetin aglycone was the best NQOl inducer, followed by quercetin-4’- 
glucoside. The 3 ’glycosylation suppressed their ability to induce NQOl (47). 
Unfortunately, Hollman et a l  showed that flavonoid glycosides are better absorbed from 
the diet than the aglycone form (48).
A correlation between NQOl expression and prevention against benzo(a)pyrene 
(BP) induced cancers (forestomach and lung) was observed in mice fed with diets
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containing 0.25 |imol o f garlic organosulfides . Diallyl disulfide (DADS) and diallyl 
trisulfide (DATS) caused a 2.4 and 1.5-fold increase in forestomach NQO l activity and 
were potent inhibitors of BP induced forestomach cancer. Diallyl sulfide’s (DAS) low 
induction of NQ O l also correlated with a low protective effect against BP induced 
forestomach carcinogenesis. In the same manner DAS was a potent inhibitor of lung 
cancer and caused a 3.2-fold induction in NQOl activity in the lung. DATS caused a 1.5- 
fold induction of NQOl activity in the lung and did not inhibit BP-induced lung cancer
(49).
Resveratrol, a polyphenolic present in grapes, showed cancer chemoprotective 
activity by inhibiting carcinogenesis at the initiation, promotion and progression steps
(50). The anti-initiation protection is associated with the induction of Phase II 
detoxification enzymes. Prochaska et al. (28) showed that resveratrol doubled NQOl 
activity in H epalc lc?  cells at a concentration of 21 pM.
Flavonoids from hops (2’, 4 ’, 6 ’, 4-OH-3-prenylchalcone and isoxanthohumol) 
also inhibited activation of aflatoxin B1 by cytochrome P450 (51), and induced NQOl in 
H epalc lc?  cells, without stimulating CY PIA I. Hop chalcones (xanthohumol and 
dehydrocycloxantohumol) also induced NQOl in a mutant cell line deficient in Ah- 
receptor (Hepa Ic lc ?  bp'^cl) (52).
Diets rich in vegetables, especially those high in cruciferous vegetables, such as 
cabbage, cauliflower, broccoli and Brussel sprouts are correlated with lower cancer 
incidences (53). Cruciferous vegetables are rich in isothiocyanates, dithiolthiones and 
indole-3 -carbinol (I3C) derivatives (54). Sulforaphane, an isothiocyanate present in 
broccoli induced N Q O l in H epalc lc?  cells. It also stimulated GST and N Q O l in
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different mouse tissues (53, 55, 56), Sulforaphane and its glucosinolate, glucoraphanin, 
inhibited the incidence and number of dimethylbenz(a)anthracene-induced mammary 
tumors in rats (56). Glucobrassicin, an I3C derivative found in high concentrations in 
cruciferous vegetables reduced the multiplicity and incidence of mammary tumors in 
mouse and rats (54, 57). I3C and related compounds can also stimulate detoxification 
enzymes, such as NQ Ol and GST (reviewed in (18)).
There is evidence of polyphenolic content in different cereal grains and legumes, 
such as wheat, barley, rice, soybeans and lentils (21, 22) (24). Rice polyphenolics 
appeared to play a protective role in oxidative stress (23). Flavonoids from cereal grains, 
such as wheat and barley, have shown antioxidant properties in vitro (21,22). As 
mentioned earlier, some antioxidants have cancer protective effects due to their ability to 
stimulate detoxification enzymes, such as NQOl (reviewed in (36)). Therefore, 
flavonoids and other polyphenolics from cereal grains and legumes may prevent cancer, 
by stimulating detoxification enzymes such as NQOl.
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Cyclooxygenase-2 and cancer chemoprevention:
Prostaglandin endoperoxide H synthase (PGHS), also known as cyclooxygenase 
(COX) is involved in the synthesis of prostaglandins (PCs) and other prostanoids from 
arachidonic acid (AA). AA is a 20-carbon polyunsaturated fatty acid that exists as an 
ester of membrane phospholipids. Activation (Figure 3) of phospholipase A] by chemical 
or mechanical stimuli results in the hydrolysis of the ester bond in membrane 
phospholipids and the release of free arachidonate (reviewed in (58, 59)). Subsequently, 
PGHS catalyzes the conversion of arachidonate and O2 to PGG2, an unstable compound 
that rapidly undergoes a two-electron reduction to PGH2.
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F igure 3. Prostanoid biosynthetic pathway (58).
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In the cyclooxygenase reaction, an arachidonyl radical is formed by abstraction of the 
(13S)-hydrogen, followed by oxygen additions at C-11 and C-15 to generate PGG2.
Then, the peroxidase activity of the enzyme reduces the hydroperoxide in position 15 to 
an alcohol, resulting in PGH2 formation (60). PGH2 is the precursor for all prostanoids, 
such as prostaglandins, prostacyclin, and thromboxanes. These compounds bind to 
specific G-protein-linked receptors and alter second messenger levels (58).
There are two known isozymes of COX: COX-1 and COX-2. Both isozymes are 
very similar structurally, with a 60% homology in amino acid sequence (58, 61). They 
are both homodimeric, heme-containing proteins with two catalytic sites (62). They also 
have similar cyclooxygenase turnover rates (-3500 mol of arachidonate/min/mol of 
dimer) and Km values for arachidonate (~5 pM). The residues involved in the catalytic 
site are conserved in both isozymes (reviewed in (58)). Despite these similarities, COX-1 
and COX-2 differ in some aspects, such as their expression patterns and their distribution. 
COX -1 is expressed constitutively in platelets, kidney, colon, stomach and most tissues, 
and it is related to the normal physiological functions of prostaglandins, such as 
cytoprotection of the gastric mucosa, regulation of renal blood flow and platelet 
aggregation (reviewed in (63)). In contrast, COX-2 levels are undetectable in most 
normal tissues, but are rapidly expressed in response to cytokines, oncogenes, tumor 
promoters and growth factors. Although COX-2 is considered the inducible isozyme, 
COX-2 is expressed constitutively in kidney and parts of the brain (61).
The genes for COX-1 and COX-2 are located in human chromosome 9q32-q33.3 
and Iq25-q25.3 respectively (reviewed in (64)). There are significant differences between 
the COX isozymes in gene structure, mRNA stability and promoter regions. COX-2
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contains in its 3’-untranslated region multiple copies of Shaw-Kamen sequences 
(AUUUA), which are responsible for the instability of COX-2 mRNA. This instability is 
characteristic of an early response gene. COX-2 also presents a TATA box in its 5’- 
flanking region, which is absent in COX-1, a classic housekeeping gene (65). CCAAT/ 
enhancer-binding protein, and cyclic AMP-responsive element are regulatory elements 
present in the 5’-flanking region. There are also an activator binding protein, SPl and 
NF-Kappa B sites (reviewed in (64)).
There are also some structural differences between COX-1 and COX-2. COX-2 
contains an additional 18-amino acid sequence close to the C terminus that is absent in 
COX-1 (58, 61). The hydrophobic channel that conducts to the active site of COX-2 also 
has an additional pocket and a slightly larger orifice than COX-1 . This is the result of the 
substitution of an isoleucine in COX-1 for a valine in COX-2. Drugs that bind to this 
additional pocket are strong selective COX-2 inhibitors (6 6 ). They also differ in their 
pattern of migration on SDS-PAGE; COX-1 moves as a single band with a relative 
molecular weight of 72 kDa while COX-2 migrates as two bands at 72 and 74 kDa. The 
72 kDa band in COX-2 has three linked oligosaccharides while the 74 band contains four 
linked oligosaccharides. Both COX-1 and COX-2 are glycosylated proteins, as N- 
glycosylation is essential for the folding of the enzymes into their active conformation.
The biosynthesis of prostaglandins can follow two kinetically different responses, 
the immediate and the delayed response. The immediate prostaglandin synthesis takes 
place minutes after the cell is exposed to a pro-inflammatory stimulus. Such stimuli result 
in increased Ca^^ levels, activation of cytosolic phospholipase Az and AA release, which 
is metabolized mainly by COX-1. The delayed synthesis of prostaglandins occurs over a
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long period of time, and involves the induction of COX-2. The amount of AA available 
determines the COX isozyme participating in the synthesis of prostaglandins. The 
involvement of COX-2 in the inflammatory delayed response is due to its ability to 
metabolize lower concentrations of AA than COX-1 (reviewed in (67)).
COX-1 (Figure 4) is part of a prostanoid biosynthetic pathway located in the 
endoplasmic reticulum (ER). PGH2 synthesized by COX-1 in the lumenal part of the ER 
migrates to the cytosolic side where it is converted to different prostanoids.
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Figure 4. Model for subcellular distribution of PGHS-1 and -2  prostanoid 
biosynthetic pathways. Abbreviations: C, carrier; E, effector; G, G protein; R, receptor; 
TXA-S, thromboxane synthase; sPLAi, secretory PLA2; CPLA2, cytosolic PLA2; PGI-S, 
prostacyclin synthase; and Rn, nuclear receptor (58).
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Prostanoids derived from this pathway migrate then to the cell surface where they bind to 
specific G-protein linked receptors. COX-2 is part of the nuclear prostanoid synthetic 
pathway. Products of this pathway act at the nuclear level and they may play a role in cell 
differentiation and proliferation (58). COX-1 derived products are involved in the normal 
functions of prostaglandins, such as cytoprotection of the gastric mucosa and regulation 
of renal blood flow. The COX-2 derived prostanoids are primarily involved in 
inflammation. This classification led to the development of COX-2 specific inhibitors. 
The new class of drugs would theoretically be able to block inflammation without 
altering the regulatory functions of the prostaglandins therefore, avoiding the adverse 
effects associated with the traditional non-steroidal antinflammatory drugs (NSAIDs). 
This view subsequently resulted in an oversimplification. COX-1 was also shown to have 
a role in the inflammatory process and several additional functions of COX-2 were also 
discovered. COX-2 is involved in the development of kidneys and maintenance of renal 
function, protection of the gastrointestinal tract from infection, ovulation and uterine 
implantation (reviewed in (63)). Observations from COX-1 and COX-2 knockout mice 
also provided additional information about their specific functions. COX-1 deficient mice 
suffered difficulty in parturition and impaired platelet aggregation, while COX-2 
deficient mice were infertile and presented kidney malfunction (6 8 ). There is evidence 
for the involvement of COX-2 in cancer. Elevated levels of prostaglandins in intestinal 
adenomas and colorectal cancers were associated with over-expression of COX-2, but not 
COX-1 (69). COX-2 is highly expressed in several tumors such as colorectal carcinoma 
(70), squamous cell carcinoma of the esophagus (71), gastric (72), pancreatic (73), and 
lung cancer (74-76).
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Epidemiological studies have shown that aspirin and other NSAIDs reduce the 
risk of colorectal cancer by 40% to 50% (77-80). Also, studies conducted by Sheng et al. 
(81) showed that a selective COX-2 inhibitor (SC-58125) reduced the tumor formation in 
nude mice after implantation of HCA-7 human colon cancer cells by 85 to 90%. Implants 
of HCT-116, lacking COX-2 expression were not affected by the administration of the 
COX-2 inhibitor (81). Oshima et al. (82) studied the role of COX-2 in tumorigenesis 
using Apc^^^^ knockout mouse, a model for human familial adenomatous polyposis 
(FAP). A reduction in the number and size of intestinal polyps was observed when the 
gene encoding for COX-2 was disrupted. The response was gene dosage-dependent, with 
an 8 6% reduction in the number of polyps in COX-2 null mice vs. a 6 6 % decrease when 
only one copy of the gene was knocked out. There was also a dose-dependent reduction 
in the number of polyps in mice treated with a COX-2 selective inhibitor (82).
The formation of new blood vessels or angiogenesis is an essential process for the 
growth of tumors beyond 2-3 mm (83). Tumors transplanted to angiogenic-deprived 
conditions remained permanently dormant. After blood supply was restored, a rapid 
tumor growth was observed (84). One promising target in cancer research is the 
inhibition of blood vessel formation by angiogenesis inhibitors. The rationale for the 
design of these drugs is that by blocking the formation of blood vessels, the oxygen and 
nutrient supply to the tumor is cutoff and the capacity of the tumor to grow and spread to 
other parts of the body is reduced. The formation of new blood vessels is the result of the 
balance between stimulatory and inhibitory growth factors, tumor suppressor genes, 
oncogenes, proteases, cytokines, signal transduction enzymes and endogenous 
modulators (85). There are a large number of endothelial cell growth stimulators.
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including vascular endothelial growth factor (VEGF), acidic and basic fibroblast growth 
factor (aFGF and bFGF), platelet-derived growth factor, epidermal growth factor, 
angiogenin, angiopoetin-1, interleukin-8 , among others. Some of the angiogenesis 
inhibitors include endostatin, angiopoetin-2 , tissue inhibitor of metalloproteinase-1 and 2 , 
thrombospondin, interpheron-alpha and interleukin-10 and 12 (85, 86 ). Among the 
stimulatory factors, VEGF and bFGF are two main targets for antiangiogenic therapy. 
VEGF and bFGF are up-regulated in many tumors where they regulate the proliferation 
and migration of endothelial cells (reviewed in (87)). Basic FGF and VEGF stimulate 
capillary tube formation in a synergistic way (reviewed in (8 8 )).
Angiogenesis is involved in the transformation of pre-malignant lesions to 
malignant lesions. There is also a correlation between the degree of vascularization of a 
tumor, its invasiveness and its metastasic potential (reviewed in (85)). The formation of 
blood vessels allows the tumor to have access to the systemic circulation, so tumor cells 
can migrate to distant locations and form metastatic foci (89). COX-2 expression in 
human colon cancer cells was associated with elevated RNA levels of metalloproteinase- 
2 and increased metastatic potential. Sulindac sulfide, a COX-2 inhibitor, reversed both 
prostaglandin production and invasiveness (90).
Aspirin and COX-2 specific inhibitor NS-398 inhibited angiogenesis in Caco-2 
colon carcinoma cells when cocultured with endothelial cells. These drugs block the 
formation of new blood vessels by inhibiting COX-2 and decreasing the synthesis of 
growth factors. COX-2 overexpression in those cells was associated with stimulation of 
endothelial cell motility and increased tube formation due to the high production of 
angiogenic factors. COX-2 inhibition reversed those effects, which suggested that the
19
prostanoids synthesized by the enzyme are involved in the angiogenic process. COX-1 
was upregulated in endothelial cells by angiogenic factors, where it may play an 
important role in angiogenesis. COX-1 inhibition may be of interest in tumors that lack 
COX -2  expression (83).
Masferrer et. al (91) also showed that the COX-2 inhibitor celecoxib inhibited 
FGF-induced comeal angiogenesis and suppressed growth in human colon cancer cells 
(HT-29) and Lewis lung carcinoma cells. The number of métastasés observed was 
reduced at high drug dosages when these cells were implanted in mice (91), Both COX-2 
expression and angiogenesis share the Ras/Raf-1/ extra-cellular signal-regulated kinase 
(ERK) pathway. NSAIDS inhibited ERK2 (MARK) activity in rat aortic endothelial cells, 
human dermal microvascular endothelial cells, and human umbilical vein endothelial 
cells (92).
COX-derived prostaglandin E l and E2 stimulated the formation of new blood 
vessels in mouse fibroblasts, an effect that was reversed by indomethacin, a nonselective 
COX inhibitor (93). Form and Auerbach (94) also showed the angiogenic potential of 
PGE2 in the chorioallantoic membrane model. PGEi pellets with releasing rates of 0.2, 
2.0, or 20 ng of PGE2/day induced the formation of new blood vessels in the membrane. 
In contrast, pellets of PGA2, PGF2, or TXB2, with similar releasing rates did not have 
that effect, suggesting that PGE2 may play a critical role in the neo-vascularization 
process (94). There is evidence of PGE2 stimulating the expression of VEGF in synovial 
fibroblasts (95) and in a non-neoplastic pre-osteoblastic cell line (96). VEGF and bFGF 
transcription were also stimulated by PGE2 in a retinal glial cell line (97).
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Flavonoids are benzo-7-pyrone derivatives that are widespread in nature. 
Preparations containing flavonoids have been used empirically in the past to treat human 
diseases (20). Flavonoids are also ingested in biologically significant concentrations as 
part of certain diets (98). There is evidence in the literature of flavonoid content in 
different cereal grains, such as wheat and barley (2 1 , 22). Flavonoids from barley, such as 
(+) catechin, (-) epicatechin and polymers of (+) catechin and (+) gallocatechin, showed 
antioxidant activity in vitro (22). Some antioxidants, such as pyrrolidinedithiocarbamate 
and N-acetylcysteine decrease COX-2 expression, PG synthesis, and proliferation in 
colorectal cancer cells (99).
Diets fortified with wheat bran oil inhibited the activity and expression of COX-2 
and inducible nitric oxide synthase (iNOS) in colon tumors. They also reduced the 
incidence, size and multiplicity of azoxymethane-induced colon cancer in rats when 
compared to animals fed with the non-fortified standard diet (100). Polyphenols from 
green and black tea, and theaflavins inhibited COX-dependent arachidonic acid 
metabolism in normal human colon by 37-62 %, at 30wg/ml (101). Possible 
chemopreventive compounds, such as quercetin, genistein, kaempferol, resveratrol and 
resorcinol, sharing a resorcin-type structure, suppressed COX-2 transcription in colon 
cancer cells (102). Flavonoids, including 3-hydroxyflavone, 3’, 4’-dihydroxyflavone, 2 ’, 
3 ’-dihydroxyflavone, fisetin, luteolin and apigenin also showed antiangiogenic and 
antiproliferative properties in vitro. They blocked bFGF- and VEGF-induced 
angiogenesis (98). Therefore, flavonoids from cereal grains may have the potential to 
inhibit the carcinogenic process at the promotion and progression step, by inhibiting 
COX-2.
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METHODS DEVELOPMENT
FLAVONOID EXTRACTION:
Preliminary studies were conducted to improve the method of extraction of 
flavonoids from cereal grains. In the first extractions, fifty grams of each grain were 
ground to a fine powder and stirred in an 80% aqueous methanol solution for 
approximately 48h. Then, the mixture was filtered using a Whatman #1 filter, and the 
methanol was evaporated in a Yamato RE 200 rotary evaporator. Next, several 
chloroform extractions were performed to the aqueous fraction to eliminate lipid soluble 
components (103). The remaining solution was extracted with equal volumes of ethyl 
acetate (103-105). The ethyl acetate was evaporated to dryness, and the residue was re­
dissolved in 1-1.5ml of 100% ethanol approximately, and stored at -20‘̂ C until assays 
were performed. We observed an insoluble residue in the bottom of the vials of several 
extracts and decided to use the supernatants for both NQOl and COX-2 assays. We 
attributed some of the variability of the results to the non-homogeneous nature of the 
flavonoid extracts. We were also concerned about the possible variability in the 
concentrations of flavonoids used, and therefore not obtaining consistent results.
In an attempt to obtain more consistent results, we prepared a new set of 
extractions, using a more standardized procedure. This second time we dissolved the 
residue obtained after evaporation of the ethyl acetate fraction in 5 ml of 100% ethanol, 
and we filtered the extracts to eliminate the insoluble residue. We also performed a 
quantification assay to measure the concentration of total phenolics present in the 
extracts. In some extracts, we observed that the aqueous fraction was more colorful than
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the ethyl acetate fraction, suggesting that flavonoid glycosides may be removed in the 
aqueous fraction.
COX-2 IMMUNOBLOTTING;
Preliminary studies were performed with the first set of extracts. In these 
experiments, U87 cells were exposed for 48 h to 5 to 100-fold dilutions of the extracts, 
depending on toxicity. The purpose of the preliminary studies was to optimize the 
dilutions of primary and secondary antibodies utilized, amount of protein loaded, time of 
blot incubation with the ECL+ detection system, and time of film exposure. For optimal 
results, 10 pg o f protein was loaded for each sample, subjected to electrophoresis for 40 
minutes at 200V, and subsequently transferred to a PVDF membrane for Ih at 90V. 
Incubation with a 1:500 dilution of COX-2 rabbit polyclonal antibody, and a 1:1000 
dilution of horseradish peroxidase (HRP) goat anti-rabbit antibody, resulted in optimal 
visualization of the COX-2 bands at 72 and 74 kDa. Beta-actin was utilized to control 
protein loading. The membrane was incubated with a 1:10,000 dilution of mouse 
monoclonal anti-actin antibody for Ih, followed by incubation with a 1:2000  dilution of 
goat anti-mouse secondary antibody for Ih. The actin bands were visualized at an 
apparent molecular weight of 42 kDa. A lysate of lipopolysaccharide (LPS)-stimulated 
RAW 264.7 macrophage cells was used as a COX-2 positive control. There is evidence in 
the literature of the LPS stimulation of both COX-2 mRNA and protein expression (106, 
107).
In our first attempt to quantify the potential COX-2 inhibition, we used the ECL 
chemiluminescence system and the N M  Image 1.60 program to quantify the bands. The
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ECL detection system has been designed for detection of immobilized proteins linked to 
a HRP antibody. Exposure of the HRP-linked antibody to the ECL reagent in alkaline 
conditions results in the oxidation of luminol, a cyclic diacylhydrazide. Following 
oxidation, luminol reaches an excited state, from which it decays to a ground state, 
emitting light at a maximal wavelength of 428 nm. The light emitted by the enhanced 
chemiluminescence reaction is maximal after 5-20 minutes, and can be captured in an 
autoradiography film, such as Hyperfilm ECL (108). Protein quantification by 
densitometry is possible due to the linear response of light emission with enhanced 
chemiluminescence. A ratio between the density of the COX-2 bands and the actin bands 
was calculated to control irregular protein loading. With this method we encountered 
several problems, such as the inability to quantify overlapping bands and the inaccuracy 
of the measurements. We decided to use a phosphoimager to quantify the bands after 
incubation with the ECL Plus enhanced chemiluminescence reagent. The ECL Plus 
system is based in the oxidation of Lumigen PS-3 achdan substrate by HRP and 
peroxide. The reaction generates an acridinium ester, which in the presence of peroxide 
in alkaline conditions produces an excited product that produces a longer and more 
intense light emission than the standard ECL system (109), A 3-4 minute exposure to 2 
ml of the ECL Plus reagent resulted in the best band detection. The maximal light 
emission was detected at 430 nm with a Fuji Film FLA-3000 phosphoimager. The Image 
Gauge software was used to quantify the bands.
Although Western blotting is considered a qualitative method for protein 
expression, we attempted to quantify the COX-2 expression to study the hypothetical 
relationship between COX-2 inhibition and polyphenolic concentration present in the
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grain extracts. High variability was observed in the quantification process. This 
variability can be attributed to the difficulty of maintaining constant parameters such as 
efficiency of the transfer, identical antibody dilutions, and equal exposure to the 
antibodies. We also encountered reproducibility problems in the results. Using virtually 
the same incubation periods with the polyphenolic extracts, dilutions of the extracts and 
amount of protein, we observed significant differences between results. To eliminate 
some variability, U87 cells were serum-deprived for 24 h prior to incubation with the 
flavonoids. The rationale for the serum starvation was to synchronize cells into the same 
phase of the cell cycle.
N Q O l ASSAY;
Preliminary studies were conducted with the first set of extracts. Ten-fold and 
100-fold dilutions of the extracts in 100% ethanol were used. Experiments were done in 
triplicate. N Q O l activity was measured in HepalclcV murine hepatoma cells (29). 
Briefly, HepalclcV cells were exposed for 48 h to the flavonoid extracts. NQOl activity 
was measured spectrophotometrically at 600nm, using NADH as an electron donor and 
2 ,6 -dichlorophenolindophenol (DCPIP) as an electron acceptor. The reduction of DCPIP 
was used as a measure of NQ Ol activity.
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MATERIALS AND METHODS
MATERIALS:
Samples of lentils, barley, and wheat were kindly donated by Terry and Taren 
Grass of Grass and Seed, Inc. of Box Elder, Montana. Other grains were purchased at the 
Good Food Store in Missoula, Montana. All reagents were at least of analytical grade. All 
chemicals were purchased from Sigma (St. Louis, MO), except buffers for 
immunoblotting and protein assay dye reagent (Bio-Rad, Hercules, CA).
CELL CULTURE:
Human glioblastoma (U87) and mouse hepatoma (HepalclcT) cell lines were 
purchased from the American Type Culture Collection (Rockville, MD). All reagents and 
media for cell culture were obtained from Life Technologies (Rockville, MD).
H epalclcT  and U87 cells were grown in minimal essential medium (MEM), 
supplemented with 10% calf serum and penicillin, streptomycin and glutamine (PSG), at 
37° C and 5% CO2 in a humidified incubator.
FLAVONOID EXTRACTION:
Fifty grams of each grain and the legume, lentils, were ground in a biomixer 
blender to a fine powder and stirred in an 80% (v/v) aqueous methanol solution for 
approximately 48h. The mixture was subsequently filtered through a Whatman #1 filter, 
and the methanol was evaporated in a Yamato RE 200 rotary evaporator. Following 
methanol evaporation, the aqueous fraction was extracted three times with equal volumes 
of chloroform to remove the lipid component, as described previously (103). The
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remaining solution was extracted with ethyl acetate (103-105). The ethyl acetate was 
evaporated to dryness, and the residue was subsequently re-dissolved in 5 ml of 100% 
ethanol, filtered and stored at -20°C until assays were performed.
TO TA L PH EN O LIC ASSAY;
The Prussian blue method was used for polyphenolic quantification of the grain 
extracts (described in (110)). When searching for a phenolic quantification method, we 
looked for a simple assay that would allow us to quantify a wide variety of grain extracts. 
The most common quantification methods of general phenolics are based on a redox 
assay, where the oxidation of phenolic groups can be detected spectrophotometrically. 
Non-phenolic antioxidants present in plants can interfere with these redox reactions. The 
Prussian blue method has less interference with non-phenolic compounds than other 
quantification assays, such as the Folin method (reviewed in (111)). The Prussian blue 
method is based on the reduction of Fe^^ to Fe^^ by polyphenols, and the subsequent 
formation of a ferricyanidine-ferrous ion complex, also known as Prussian blue. This 
colored complex can be read spectrophotometrically at 720 nm.
One hundred pi o f each extract was added to 50 ml o f distilled water in a 125 ml 
Erlenmeyer flask. To each flask, 3 ml of 0.1 M FeNH4(S04)2  in 0.1 M HCl was added at 
1 minute intervals, swirling after each addition. Following a 20 minute interval, timed 
additions of 3 ml of 8 mM K3Fe(CN)ô were started. Solutions were mixed and after a 20- 
minute incubation period, the absorbance was read at 720 nm using a Beckman DU 7500 
spectrophotometer (111). The timing of the additions was essential for obtaining 
consistent results. A time-dependent increase in the absorbance was observed. A standard
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curve was obtained following the same timed process, using (+)-catechin as a standard 
phenolic. Catechin concentrations of 0 mM, 5mM, lOmM, 15mM and 20mM (in 100% 
ethanol) were used to build the standard curve. A 100% ethanol blank was used to correct 
the absorbance.
NQOl ACTIVITY ASSAY:
H epalclcT  cells were grown to 50-60% confluency in the conditions described 
above. Cells were then exposed for 48h to fresh medium containing the flavonoid extracts 
in ethanol (1%, by volume). A 10-fold dilution of the original extracts was prepared in 
100% ethanol. Three hundred pi o f the diluted extracts were added to 30 ml o f media.
Ten ml of media/extract were then pipeted into each petri dish. Following the period of 
exposure, media was removed and cells were washed with 2  ml of phosphate buffered 
saline (PBS). Subsequently, cells were trypsinized and centrifuged for 5 min, at 4°C and 
2500 r.p.m in a Tomy TX-160 high-speed refrigerated microcentrifuge. The supernatant 
was removed and cells were washed twice by re-suspending the cells in 4 ml of PBS 
followed by centrifugation. The pellet was re-suspended in 1 ml of Tris-Sucrose solution, 
then sonicated and stored at -20°C until the assay was performed. NQOl activity was 
measured spectrophotometrically in a reaction mixture containing Tris-HCl 25mM (PH 
7.4), 0.7 mg/ml BSA (bovine serum albumin) and, 0.1% Tween 20. NADH was used as 
an electron donor and DCPIP as an electron acceptor as described previously (29). 
Twenty pi o f NADH was added to the reaction mixture in a 1 ml plastic cuvette, followed 
by addition of 20 pi of the cell sonicate. The reaction was started by the addition of 20 pi 
of DCPIP to the reaction mixture containing both NADH and the cell sonicate. The
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disappearance of DCPIP was measured at 600nm for 30s in a Beckman DU 7500 
spectrophotometer.
N Q O l activity was measured with and without addition of dicoumarol, to 
calculate the activity due to this enzyme and to eliminate other possible causes of DCPIP 
reduction (27). Dicoumarol is a potent inhibitor of NQ O l, with a Ki of 10 ® M. It inhibits 
N Q O l by competing with NADH and NADPH (29). The portion of activity inhbited by 
dicoumarol was used as a measure of NQOl activity.
COX-2 IMMUNOBLOT ANALYSIS:
U87 cells were grown to 50% confluency in the conditions described above.
Cells were then serum deprived for 24 h in order to synchronize them into the same phase 
of the cell cycle. After the period of serum starvation, cells were fed with normal medium 
and exposed to the flavonoid extracts at two different concentrations:
-Ix  dilution of the extracts: 300 pi o f full strength extract in 30 ml o f medium.
-lOx dilution of the extracts: 30 pi o f full strength extract + 270 pi of 100% 
ethanol, in 30 ml of medium. In both cases, 10 ml of media/extracts was added to each 
petri dish. Three plates were used per sample. Cells were then scraped serially in 750 pi 
of two-fold concentrated Laemmli buffer [10% SDS, glycerol, 1 M Tris-HCl (PH 6 .8 ), 
supplemented with protease inhibitors (40 pg/ml PMSF, 2 pg/ml aprotinin and 2 pg/ml 
leupeptin)]. Samples were passed through an 18 g and a 25 g needle and boiled for five 
minutes. Samples were stored at -20° C until further use.
Samples containing a total of 10 pg of protein were then added to SDS-PAGE 
loading buffer [62.5 mM Tris-HCl (PH 6 .8), 2% SDS, glycerol, bromophenol blue and
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5% beta-2-mercaptoethanol] and heated for 5 min at 100° C. The samples were 
subsequently loaded onto a 10% polyacrylamide gel and subjected to electrophoresis for 
40 minutes, at 200V in a Bio-Rad mini-protean 3 cell (Bio-Rad, Hercules, CA). Gels 
were subsequently transferred to a PVDF membrane (Osmonics, Westborough, MA) for 
Ih, at 90 V.
The membranes were blocked with 3% non-fat milk in TBST [lOOmM Tris Base, 
150mM NaCl, 0.1% Tween 20 (pH 8.0)], and subsequently incubated with a 1:500 
dilution of COX-2 rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, 
CA), and a 1:10,000 dilution of mouse monoclonal anti-actin antibody (Oncogene, 
Boston, MA) for 1 h. Following, a 1:1000 dilution of goat anti-rabbit secondary antibody 
(Vector Laboratories, Burlingame, CA), and a 1:2000 dilution of horseradish peroxidase 
goat anti-mouse antibody (Oncogene, Boston, MA) were applied. A macrophage cell 
line, RAW 264.7 was used as a COX-2 positive control. Bands were visualized by ECL 
Plus enhanced chemiluminescence system (Amersham Pharmacia Biotech, Piscataway, 
NJ). Protein bands in Western blots were quantified by densitometry, using a Fuji Film 
FLA-3000 phosphoimager.
BRADFORD PROTEIN ASSAY;
Protein concentrations were determined using the Bradford protein assay (112) 
from Biorad (Hercules, CA). The principle of this assay is the change of color that occurs 
when protein binds to the Coomassie blue dye present in the Bradford reagent. The 
Coomassie blue dye binds mainly to aromatic and basic amino acids, especially to 
arginine, changing the absorbance from 465 nm to 595 nm. The change of color observed 
is proportional to the protein concentration.
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BSA concentrations of 0 ,100, 200, 300,400, and 500 ng/ml were used for a 
standard curve. Samples and standards were exposed to a 5-fold dilution of the reagent 
for at least 5 minutes. Absorbance was read in a Beckman DU 7500 spectrophotometer at 
595 nm.
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RESULTS
Preliminary studies were conducted with a first set of extracts. Briefly, fifty grams 
of each grain were ground to a fine powder, stirred in 80% aqueous methanol for 48 h, 
and extracted with chloroform and ethyl acetate, as described in the methods section. The 
ethyl acetate fraction was evaporated, and the residue was dissolved in 1- 1.5 ml of 100% 
ethanol. We attributed part of the variability of the results observed with the first set of 
extracts to the non-homogeneous nature of the flavonoid extracts. In order to obtain more 
consistent results, we prepared a second set of extracts, in which the residue obtained 
after evaporation of the ethyl acetate fraction was re-dissolved in 5 ml of 100% ethanol, 
and filtered to eliminate the insoluble residue. The Prussian blue method was used to 
quantify the polyphenolic content of the second set of extracts.
Polyphenolic quantification of extracts from cereal grains and legumes:
Figures 5, 6 , and 7, show the polyphenolic content of the second set of extracts. 
Dehulled barley and row barley have the highest concentrations of total phenolics, with 
concentrations of 10.3 ± 0.5 mM and 9.8 ± 0.5 mM, respectively. All types of wheat 
ranged from 0.20 ± 0.47 x 10  ̂mM to 0.56 ± 0.02 mM, containing the lowest 
polyphenolic concentrations of the grains analyzed. A marked difference was observed in 
the polyphenolic concentrations of brown rice and wild rice. Wild rice, the most 
unprocessed form, contains a phenolic concentration 5 times higher than brown rice (3.7 
±0 .1  mM vs 0.7 ±0 .1  mM). Oats, rye, lentils and maize have a phenolic content of 1.2 ± 
0.04 mM, 0.9 ± 0.05 mM, 3.9 ± 0.3 mM, and 1.5 ± 0.1 mM, respectively.
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Effect of flavonoids from cereal grains and legumes on NQOl activity:
Two different sets of extracts were used to evaluate the effect of flavonoids from 
cereal grains and legumes on the enzymatic activity of NQ Ol. Preliminary studies done 
with the first set of extracts (Tables 1, 2, 3, and Figure 8), showed a significant NQOl 
(P<0.05) induction with most extracts. H epalclc? cells were exposed for 48 h to 10-fold 
dilutions of lentils, kamut, spring hard wheat, spring red wheat, winter wheat, dehulled 
barley, and spelt extracts. The extracts of oats, rye, row barley, maize, wild rice, and 
brown rice were used at 100-fold dilution to avoid the toxicity observed with more 
concentrated solutions. In the wheat group, induction rates ranged from a 1.6-fold 
induction with spring red wheat to a 3.9-fold induction with spelt. The induction 
observed with spelt polyphenols is considerable when compared to the NQOl induction 
observed with standard phenolic inducers, such as tert-Butylhydroquinone (t-BHQ) and 
hydroquinone (HQ), used as positive controls. Exposure of t-BHQ (20 pM) and HQ (20 
pM) (Table 3) to H epalc lc?  cells for 48 h resulted in a 3.6, and 3.2-fold NQOl 
induction, respectively.
Row barley polyphenols caused a 2.6-fold induction in the enzyme’s activity, 
whereas dehulled barley caused a 1.4-fold induction. Incubation with wild rice 
polyphenols caused a 2.7-fold induction, but only a 1.3-fold induction was observed 
when cells were exposed to brown rice polyphenols. A 2.5, 2.4, 2.9, and 1.4-fold 
induction of N Q O l activity was observed with the extracts of lentils, oats, rye and maize, 
respectively. The NQ O l induction observed with maize and brown rice was not 
significant. When experiments were repeated with the second set of extracts (Table 4, 5, 
and Figure 9), only the extracts of spring red wheat, winter wheat, wild rice, and lentils
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caused a significant NQOl induction. A ten-fold dilution of the second set of extracts
was exposed to H epalc lc?  cells for 48h. A 1.5 (P<0.05), 1.6 (P<0.01), 1.5 (P<0.05) and
1.8-fold (P<0.01) NQOl induction was observed with the flavonoids of spring red wheat,
winter wheat, wild rice, and lentils, respectively. No correlation was observed between
the amount of polyphenolics in the extracts and the NQOl induction.
Effect of flavonoids from cereal grains and legumes on the inhibition of COX-2 
protein expression:
Preliminary studies conducted with the first set of extracts showed COX-2
inhibition with oats and rye polyphenols (Figure 10), suggesting their potential cancer 
preventive properties. In these experiments, U87 cells were exposed to a 5 to 10-fold 
dilution of the extracts for 48 h. Further experiments were conducted with the second set 
of extracts to evaluate these properties.
A 10-fold dilution of the extracts and the undiluted extracts were used to 
investigate the inhibition of COX-2 expression in U87 cells. No significant COX-2 
inhibition was observed after a 48-h exposure to a 10-fold dilution of the extracts or to 
the extracts at full strength. COX-2 Western blots of U87 cells incubated with a 10-fold 
dilution of the extracts are shown in Figures 11 and 12. Figures 13 and 14 show the 
COX-2 immunoblots of cells incubated with the polyphenolic extracts at full strength. 
Oats and dehulled barley extracts were toxic to U87 cells when used at full strength. Both 
extracts caused the de-attachment of the cells from the bottom of the plates.
The quantification of the bands by densitometry (Tables 6 , 7, 8 and 9) confirmed 
the results observed in the Western blots. The density of the actin bands was used to 
correct differences in protein loading.
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Figure 5. Polyphenolic quantification of the various grain and legume extracts, 
using the Prussian blue method. The extracts were prepared from 50 g of each grain and 
legume. The formation of the ferricyanidine-ferrous ion complex was read 
spectrophotometrically at 720 nm. Bars represents the means ± S.D. (n=3).
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□  Brown Rice
I Wild Rice
Figure 6, Polyphenolic content of brown rice, and wild rice, using the Prussian 
blue method. The extracts were prepared from 50 g of each grain. The formation of the 
ferricyanidine-ferrous ion complex was read spectrophotometrically at 720 nm. Bars 
represents the means ± S.D. (n=3).
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Figure 7. Polyphenolic quantification of wheat extracts, using the Prussian blue 
method. The extracts were prepared from 50 g of each grain. The formation of the 
ferricyanidine-ferrous ion complex was read spectrophotometrically at 720 nm. Bars 
represents the means ± S.D. (n=3).
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Table 1. Effect of flavonoids from the first set of extracts on NQOl activity in
HepalclcT cells after 48 h of treatment
Treatment Protein (mg/ml) NQ O l Activity 
(pmol/min/mg)
Ethanol ( 1%) 
Lentils (O.lx)
1.211 ±0.097 
1.060 ±0.087
0.088 ± 0.017 
** 0.224 ± 0.007
Ethanol ( 1%)
Dehulled barley (O.lx)
1.361 ±0.081 
1.375 ±0.080
0.071 ±0.006 
**0.100 ±0.004
Ethanol (1%)
Spring red wheat (O.lx) 
W inter wheat (O.lx)
1.528 ±0.081 
1.277 ±0.283 
1.481 ±0.139
0.053 ± 0.002 
*0.086 ± 0 .0 1 0  
**0.109 ±0.003
Ethanol (1%)
Oats (0.01 x)
Row barley (0.0 Ix) 
Rye (O.Olx)
1.296 ±0.077 
1.378 ±0.085 
1.400 ±0.018 
1.367 ±0.230
0.027 ± 0.003 
*0.066 ±0.015 
**0.072 ±0.003 
** 0.080 ± 0.004
* Values are the means ± S.D. (n=3).
* = The N Q O l activity is significantly different than that observed with the control 
(P<0.05).
** = P<0.01.
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Table 2. Effect of flavonoids from the first set of extracts on NQOl activity in
HepalclcT cells after 48 h of treatment
Treatment Protein (mg/ml) NQ O l Activity 
(pmol/min/mg)
Ethanol (1%)
Kamut (O.lx)
Spring hard wheat (O.lx) 
Spelt (O.lx)
1.161 ±0.152 
1.148 ±0.199 
1.335 ±0.173 
0.832 ±0.021
0.069 ±0.010 
** 0.176 ±0.023 
**0.161 ±0.003 
** 0.267 ± 0.007
Ethanol ( 1%) 
Maize (0.0 Ix) 
W ild rice (O.Olx)
1.212  ±0.026 
1.568 ±0.071 
1.673 ±0.172
0.024 ±0.013 
0.034 ± 0.006 
* 0.066 ± 0.005
Ethanol (1%) 
Brown rice (O.Olx)
0.977 ± 0.060 
0.887 ±0.047
0.116 ±0.027 
0.153 ±0.016
“Values are the means ± S.D. (n=3).
* = The N Q O l activity is significantly different than that observed with the control 
(P<0.05).
** = P<0.01.
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Table 3. Effect of hydroquinone (HQ) and tert-butyl hydroquinone (t-BHQ) on NQOl
activity in HepalclcT cells after 48 h of treatment
Treatment Protein (mg/ml) NQ O l Activity 
(pmol/min/mg)
Ethanol (1%) 
t-BHQ (20 pM)
0.601 ±0.306 
0.604 + 0.321
0.181 ±0.053 
** 0.646 ± 0.274
Ethanol ( 1%) 
HQ (20 pM)
0.330 ±0.036 
0.319 ±0.015
0.177 ±0.040 
**0.575 ±0.088
“Values are the means ± S.D. of at least three experiments (n=3-6).
** = The N Q O l activity is significantly different than that observed with the control 
(P<0.01).
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Figure 8 . N Q O l induction in H epalc lc?  cells after exposure to the first set of flavonoid extracts for 48 h. Ten-fold and 100- 
fold dilution of the extracts were used, depending on toxicity. Each bar represents the ratio between the NQ O l activity observed with 
a sample, and the enzyme’s activity observed with a 1% ethanol control. Each data point represents the mean ± S.D. (n=3). * = The 
enzyme’s activity is significantly increased compared to control (P<0.05). ** = P<0.01.
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Table 4. Effect of flavonoids from the second set of extracts on NQOl activity in
H epalclc? cells after 48 h of treatment
Treatment Protein (mg/ml) NQOl Activity 
(pmol/min/mg)
Ethanol (1%)
Kamut (O.lx)
Spring hard wheat (O.lx) 
Spelt (O.lx)
0.970 ± 0.564 
0.859 ± 0.326 
0.896 ±0.563 
1.089 ±0.491
0.096 ±0.041 
0.122 ±0.048 
0.082 ± 0.013 
0.102 ±0.029
Ethanol (1%) 
Maize (O.lx) 
Wild rice (O.lx)
0.663 ±0.130 
0.885 ± 0.306 
0.763 ±0.207
0.111 ±0.029 
0.146 ±0.031 
*0.164 ±0.044
Ethanol (1%)
Oats (O.lx)
Dehulled barley (O.lx)
0.696 ± 0.084 
0.784 ±0.130 
0.683 ±0.250
0.106 ±0.084 
0.129 ±0.013 
0.137 ±0.027
® Values represent the means ± S.D. (n=6 ).
* = The N Q O l activity is significantly different than that observed with the control 
(P<0.05).
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Table 5. Effect of flavonoids from the second set of extracts on NQOl activity in
H epalclc? cells after 48 h of treatment
Treatment Protein (mg/ml) NQOl Activity 
(pmol/min/mg)
Ethanol ( 1%)
Row barley (O.lx) 
Brown rice (O.lx)
1.062 ±0.434 
0.968 ±0.321 
1.163 ±0.334
0.077 ± 0.022 
0.091 ± 0.032 
0.097 ± 0.061
Ethanol (1%)
Spring red wheat (O.lx) 
Winter wheat (O.lx)
1.130 ±0.338 
1.126 ±0.368 
1.155 ±0.143
0.056 ±0.011 
* 0.087 ± 0.026 
**0.092 ±0.021
Ethanol (1%) 
Lentils (O.lx)
0.823 ±0.096 
0.818 ±0.167
0.071 ±0.028 
**0,125 ±0.022
Ethanol (1%) 
Rye (O.lx)
0.604 ± 0.047 
0.624 ± 0.057
0.125 ±0.025 
0.117 ±0.015
 ̂Values represent the means ± S.D. (n=6 ).
* = The N Q O l activity is significantly different than that observed with the control 
(P<0,05).
** = P<0.01.
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Figure 9. NQ O l induction in H epalc lc?  cells after exposure to a ten-fold dilution of the second set of flavonoid extracts for 
48 h. Each bar represents the ratio between the NQOl activity observed with a sample, and the enzyme’s activity observed with a 1% 
ethanol control. Each data point represents the mean ± S.D. (n=6). * = The enzyme’s activity is significantly increased compared to 
control (P<0.05). ** = P<0.01.
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Figure 10. COX-2 immunoblot preliminary studies. U87 human gliobastoma 
cells were exposed to a 5-fold dilution of the first set of extracts. A total of 25 pg of 
protein of each sample was loaded. RAW 264.7, a macrophage cell line, was used as a 
positive control. Bands at 72 kDa correspond to COX-2. Expression o f P-actin (42 kDa) 
was used as a control for gel loading. One of three independent experiments is shown 
(n=3).
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Figure 11. Immunoblot analysis of COX-2 in U87 human gliobastoma cells, 
following a 48 h exposure to a 10-fold dilution of the different extracts. A total of 10 pg 
of protein was loaded for each sample. RAW 264.7, a macrophage cell line, was used as a 
positive control. Bands at 72 kDa and 74 kDa correspond to two different isoforms of 
COX-2. Expression o f P-actin (42 kDa) was used as a control for gel loading. One of 
three independent experiments is shown (n=3-5).
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Figure 12. Immunoblot analysis of COX-2 in U87 human gliobastoma cells, 
following a 48 h exposure to a 10-fold dilution of the different extracts. A total of 10 pg 
of protein was loaded for each sample. RAW 264.7, a macrophage cell line, was used as a 
positive control. Bands at 72 kDa and 74 kDa correspond to two different isoforms of 
COX-2. Expression o f p-actin (42 kDa) was used as a control for gel loading. One of 
three independent experiments is shown (n=3-5).
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Table 6. COX-2 expression in U87 cells exposed to a O.lx dilution of the polyphenolic
extracts
Treatment Ratio COX-2 / p-actin expression
Ethanol (1%) 0.720 ± 0.222
W inter wheat (O.lx) 0.677 ±0.257
Spring red wheat (O.lx) 0.862 ±0.276
Row barley (lOx) 0.828 ±0.376
Lentils (O.lx) 0.882 ± 0.474
Brown rice (O.lx) 0.901 ±0.331
Wild rice (O.lx) 0.903 ±0.479
Maize (O.lx) 0.871 ±0.286
 ̂Values are the means ± S.D. (n=3-5). Quantification was done by densitometry. None o 
the samples were statistically different than control.
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Table 7. COX-2 expression in U87 cells exposed to a O.lx dilution of the polyphenolic
extracts
Treatment Ratio COX-2 / p-actin expression
Ethanol (1%) 0.733 ± 0.256
Dehulled barley (O.lx) 0.869 ± 0.395
Oats (O.lx) 0.837 ±0.391
Rye (O.lx) 0.723 ± 0.336
Spring hard wheat (O.lx) 0.742 ± 0.394
Kamut (O.lx) 0.670 ±0.351
Spelt (O.lx) 0.673 ±0.386
 ̂Values are the means ± S.D. (n=3-5). Quantification was done by densitometry. None of 
the samples were statistically different than control.
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Figure 13. Immunoblot analysis of COX-2 in U87 human gliobastoma cells, 
following a 48 h exposure to the different extracts at full strength. A total of 10 pg of 
protein was loaded for each sample. RAW 264.7, a macrophage cell line, was used as a 
positive control. Bands at 72 kDa and 74 kDa correspond to two different isoforms of 
COX-2. Expression o f p-actin (42 kDa) was used as a control for gel loading. One of 
three independent experiments is shown (n=3).
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Figure 14. Immunoblot analysis of COX-2 in U87 human gliobastoma cells, 
following a 48 h exposure to the different extracts at full strength. A total of 10 pg of 
protein was loaded for each sample. RAW 264.7, a macrophage cell line, was used as a 
positive control. Bands at 72 kDa and 74 kDa correspond to two different isoforms of 
COX-2. Expression o f p-actin (42 kDa) was used as a control for gel loading. One of 
three independent experiments is shown (n=3).
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Table 8. COX-2 expression in U87 cells exposed to the polyphenolic extracts at full
strength
Treatment Ratio COX-2 / P-actin expression
Ethanol (1%) 0.700 ± 0.343
Rye (F.S.) 0.615 ±0.358
Spring hard wheat (F.S.) 0.430 ± 0.335
Kamut (F.S.) 0.544 ±0.278
Spelt (F.S.) 0.737 ±0.340
“ Values are the means ± S.D. (n=3). Quantification was done by densitometry. None of 
the samples were statistically different than control. F.S.= full strength.
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Table 9. COX-2 expression in U87 cells exposed to the polyphenolic extracts at full
strength
Treatment Ratio COX-2 / p-actin expression
Ethanol (1%)
Winter wheat (F.S.) 
Spring red wheat (F.S.) 
Row barley (F.S.)
0.695 ± 0.076 
0.733 ± 0.088 
1.007 ±0.221 
0.975 ± 0.428
Ethanol (1%) 0.695 ± 0.076
Lentils (F.S.) 0.796 ±0.248
Brown rice (F.S.) 0.741 ±0.130
Wild rice (F.S.) 0.736 ± 0.060
Maize (F.S.) 0.814 ±0.419
® Values are the means ± S.D. (n=3). Quantification was done by densitometry. None of 
the samples were statistically different than control. F.S.= full strength.
54
DISCUSSION
Phytochemicals present in fruits, vegetables and whole grains have the potential 
to inhibit the development of cancer. Among these phytochemicals, flavonoids and other 
polyphenolics present in fruits and vegetables have been the center of extensive study in 
the past. Several mechanisms have been proposed for their protective properties. 
Flavonoids and other polyphenolics can block the initiation of cancer by inhibiting phase 
I enzymes, inducing phase II enzymes, and by scavenging reactive oxygen species (ROS) 
that can react with DNA and cause mutations. They can also modulate the promotion and 
progression of cancer by altering apoptosis and angiogenesis (19, 98).
In the present work, we studied the potential cancer preventive properties of 
flavonoids and other polyphenolics present in various cereal grains. Cereal grains are a 
major component of western diets. In the past, cereal grains and legumes have been 
studied mainly for their fiber content and their beneficial effects in the protection against 
colon cancer (2). However, little attention was paid to the possible protective effect of the 
phenolic fraction of those grains. Cereal grains and legumes are a rich source of 
phenolics, providing approximately 44 mg of flavonoids per day in the diet (15). Some of 
these polyphenolics have shown antioxidant activity in vitro (22) and have the potential 
of being cancer preventive (reviewed in (113)). We were interested in studying the 
potential cancer preventive properties of the flavonoids present in a variety of cereal 
grains. Our goal was to study the capacity of the various flavonoid extracts to block the 
initiation of cancer by inducing N Q O l, and to inhibit the promotion and progression of 
cancer by inhibiting COX-2.
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ROS generated in the metabolism of carcinogens can cause DNA damage, which 
is an important factor in cancer initiation. Animals have developed antioxidant defense 
systems against toxic compounds. Induction of Phase II enzymes such as GST, NQOl 
and UDP-GT, and elevated levels of glutathione are examples of these antioxidant 
defense mechanisms (25). NQOl is a two-electron quinone reductase that reduces 
quinones directly to hydroquinones, avoiding the formation of free radicals generated in 
the redox cycling of an intermediate semiquinone (27,29, 30). Induction of Phase II 
detoxification enzymes by natural or synthetic compounds is a well-established strategy 
towards cancer chemoprevention (25, 26, 33-35). The induction of NQOl activity has 
protective effects against toxicity, mutagenesis and carcinogenesis (33, 35-37).
Animal and epidemiological studies have shown the potential of flavonoids as 
cancer chemopreventive agents. The cancer-protective effects of flavonoids have been 
associated, in large part, with their antioxidant properties. Besides their ability to 
scavenge free radicals, flavonoids can also act as chelators of metal ions and as 
modulators of antioxidant enzymes (114). The latter property raised our interest. In 
particular, we were interested in the capacity of flavonoids from different grains to 
stimulate the activity of NQ O l.
Preliminary studies of NQ O l activity (Figure 8) showed a significant induction of 
the enzyme after a 48 h exposure to the first set of polyphenolic extracts. H epalclc7 cells 
were exposed to 10-fold dilutions of the lentils, kamut, spring hard wheat, spring red 
wheat, winter wheat, dehulled barley, and spelt extracts. One hundred-fold dilutions of 
the extracts of oats, rye, row barley, maize, wild rice, and brown rice were used due to the 
toxicity observed with more concentrated solutions. In the wheat group, induction rates
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ranged from a 1.6-fold induction with spring red wheat to a 3.9-fold induction with spelt. 
The induction observed with spelt polyphenols is quite remarkable when compared to the 
N Q O l induction observed with standard phenolic inducers, such as t-BHQ and HQ (28). 
Exposure o f t-BHQ (20pM) and HQ (20 pM) to H epalclc? cells for 48 h resulted in a 
4.2- and 3.2-fold induction in the enzyme’s activity, respectively (Table 3). Another 
interesting observation was the difference between the N QOl induction rates after 
incubation with the extracts of row barley and dehulled barley. Row barley, the most 
unprocessed form of barley tested, produced a 2.6-fold induction of the enzyme’s 
activity, whereas dehulled barley produced a 1.4-fold induction. Also outstanding is the 
difference in enzyme induction observed between wild rice and brown rice. A 2.7-fold 
induction was obtained with wild rice, but only a 1.3-fold induction was observed with 
brown rice. In most refining processes, phytochemicals and nutrients present in the outer 
parts of the grains are removed, reducing the nutritional value of the grains (reviewed in 
(10)). The N Q O l results obtained in these experiments suggest that their potential cancer 
preventive properties may also be reduced during the refining process. A 2.5, 2.4, 2.9, 
and 1.4-fold induction of NQ Ol activity was observed with the extracts of lentils, oats, 
rye and maize, respectively. The NQOl induction observed with maize and brown rice 
was not significant.
When experiments were repeated with a new set of extracts, a significant NQOl 
induction (Figure 9) was observed in H epalc lc?  cells after a 48-h exposure to a 10-fold 
dilution of the wild rice, lentils, spring red wheat and winter wheat extracts. A 1.5,1.6,
1.5, and 1.8-fold NQOl induction was observed with the flavonoids of spring red wheat, 
winter wheat, wild rice, and lentils, respectively. In the second set of extracts, the residue
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obtained after evaporation of the ethyl acetate fraction was dissolved in 5 ml of 100% 
ethanol and filtered to eliminate the insoluble residue. Results from the phenolic 
quantification of the extracts (Figures 5,6, and 7) show that dehulled barley and row 
barley have the highest concentrations in total phenolics, with concentrations of 10.3 mM 
and 9.8 mM, respectively. All types of wheat ranged from 0.3 mM to 0.6 mM, containing 
the lowest polyphenolic concentrations of the grains analyzed. Wild rice, the most 
unprocessed form, contains a phenolic concentration 5 times higher than brown rice (3.7 
mM vs 0.7 mM). Oats, rye, lentils and maize have a phenolic content of 1.2 mM, 0.9 
mM, 3.9 mM, and 1.5 mM, respectively. No correlation between the amount of 
polyphenolics and N QOl induction was observed.
One possible explanation for the results observed in these experiments is that the 
concentration of flavonoids in some extracts of the second set may be insufficient to 
cause a significant N QOl induction. In the literature, a wide range of concentrations of 
flavonoids and other polyphenolics caused induction of NQOl. Exposure of quercetin 
(15jxM) to a human breast carcinoma cell line (MCF-7) for a period o f 24 h, resulted in a 
two-fold increase in NQ O l activity (46). The polyphenolic resveratrol doubled NQOl 
activity in H epalc lc7  cells at a concentration o f 21 pM (28). Enterolactone and genistein 
doubled the acitivity of N Q O l in colonic Colo 205 cells at concentrations of 0.04 and
0.14 pM, respectively. A 2 to 3- fold NQOl induction was observed in the same cell line 
with biochanin A (1.1 pM) and coumestrol (12.0 pM) (42). The flavanone 6,8- 
diprenylnaringenin present in hops doubled NQOl activity at a 4,4 pM concentration in 
H epalclc7  cells (115).
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Although lower concentrations of flavonoids have been previously shown to induce 
N Q O l, the flavonoids contained in our extracts may not be potent enough to stimulate 
N Q O l at these concentrations. Flavonoid glycosides lost in the extraction process may 
also contribute to NQOl induction. Collection of the aqueous and lipid fractions should 
be considered in future studies. There is also the possibility of losing active compounds 
during the filtration of the extracts. This last hypothesis would explain the differences 
seen in the enzyme’s activity with the two sets of extracts.
In future studies, serial dilutions of the extracts should be made to assure that the 
lack of N Q O l induction is not due to a low flavonoid concentration. An assay for 
detection of N Q O l inducers described by Prochaska et al. (28), may be useful for this 
purpose. In that assay, H epalc lc?  cells are plated in 96 well plates, and incubated for 24h 
with the potential anticarcinogenic agents. Cells are lysed and assayed in a solution 
containing 2-methyl-1,4-naphtoquinone (menadione), [3-(l,5,-di-methylthiazo-2-yl)-2,5- 
diphenyltetrazolium bromide] (MTT), and a NADPH-generating system. NQOl reduces 
menadione to menadiol, using NADPH as a cofactor. Menadiol spontaneously reduces 
MTT to formazan dye. The production of the formazan dye can be monitored 
spectrophotometrically at 610 nm, and used as a measure of NQO l activity (28).
We were also interested in another approach towards cancer chemoprevention 
with dietary flavonoids: the inhibition of COX-2. COX-2, a rate-limiting enzyme in the 
biosynthesis of prostaglandins from AA, has also raised interest as a possible way of 
inhibiting cancer growth. Observations from epidemiological studies have shown that 
aspirin and other NSAIDs reduced the risk of colorectal cancer by 40-50% (reviewed in 
(61)). Sulindac, a COX inhibitor, also reduced the size and number of polyps in patients
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with FAP (reviewed in (61)). More evidence of the involvement of COX-2 in 
tumorigenesis came from the studies of Oshima et al. (82), in a mouse model for human 
FAP. A reduction in the number and size of intestinal polyps was observed when the gene 
encoding for COX-2 was disrupted, and when mice were treated with a COX-2 selective 
inhibitor (82). COX-2 is upregulated in many tumors, where it may play a critical role in 
the formation of blood vessels (116). The formation of new blood vessels is essential for 
the delivery of oxygen and nutrients to the tumor and ultimately for tumor growth. The 
degree of vascularization of a tumor is related to its invasiveness and metastatic potential 
(reviewed in (85)). PGE2 has been shown to induce the formation of new blood vessels in 
the chorioallantoic membrane model (94). PGE2 stimulated the expression of VEGF in 
synovial fibroblasts (95) and in pre-osteoblastic cells (96). VEGF and bFGF transcription 
were also stimulated by PGE2 in cultured rat Muller cells (97).
Flavonoids have previously been shown to possess antiproliferative and 
antiangiogenic properties in vitro by blocking bFGF- and VEGF-induced angiogenesis 
(98). Polyphenols from green and black tea, and theaflavins inhibited COX-dependent 
arachidonic acid metabolism in normal colon cells by 37-62 % at 30 pig/ml (101).
Possible chemopreventive compounds, such as quercetin, genistein, kaempferol, 
resveratrol and resorcinol, sharing a resorcin-type structure, suppressed COX-2 
transcription in colon cancer cells (102).
Preliminary studies with the first set of extracts showed COX-2 inhibition with 
oats and rye polyphenols (Figure 10), suggesting the potential of these compounds to 
inhibit carcinogenesis at the promotion and progression step. Further research with the 
second set of extracts was conducted to investigate this effect. Two different extract
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dilutions were used to evaluate the inhibition of COX-2 expression in U87 cells. In both 
cases, cells were exposed to the polyphenolic extracts for a period of 48 hours. A final 
concentration o f 2 pM-100 pM of the polyphenols was obtained when using the extracts 
at full strength, and a concentration o f 0.2 pM -10 pM when a 10-fold dilution was 
prepared. As shown in Figures 11 and 12, there was no inhibition of COX-2 expression 
observed when using a 10-fold dilution of the extracts. Extracts at full strength were used 
as an attempt to observe the inhibition of COX-2 expression, and to assure that the lack 
of inhibition was not due to a low concentration of the polyphenols in the extracts. When 
using the polyphenolic extracts at full strength (Figure 13 and 14), there was also no 
COX-2 inhibition observed. The quantification of the bands by densitometry (Tables 6 ,7 , 
8, and 9) confirmed the results observed in the Western blots.
One possible explanation for these results is that potentially active compounds 
present in the extracts may be lost during the filtration process. With the extraction 
method utilized, flavonoid glycosides were also eliminated in the aqueous fraction. In the 
literature, flavonoid aglycones appear as the main inhibitors of COX-2 enzymatic activity 
in vitro, whereas flavonoid glycosides are less inhibitory or non-inhibitory (117,118). 
Although flavonoid glycosides do not inhibit COX-2 activity in vitro, they may play an 
important role in vivo, as they are better absorbed from the diet than the flavonoids 
aglycones (48). A study by Reddy et al. (100), also showed that the oil fraction of wheat 
bran had cancer protective effects. Wheat bran oil inhibited the activity and expression of 
COX-2 and inducible nitric oxide synthase (iNOS) in colon tumors. The incidence, size 
and multiplicity of AOM-induced colon tumors in rats were also reduced when compared 
to animals fed with the non-fortified standard diet (100). Lipid soluble components of the
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cereal grains tested may be involved in COX-2 expression inhibition. With the extraction 
method employed, the lipid soluble compounds are removed in the chloroform extraction. 
Collection of an aqueous fraction, a lipid soluble fraction and an ethyl acetate fraction of 
the extracts should be considered in future studies. Another observation made in the 
culture of the U87 cells was that the flavonoid extracts of oats and dehulled barley were 
toxic when they were used at full strength. The cytotoxic properties of flavonoids and 
other polyphenols have been observed (115,119,120), and some flavonoids, such as 
chalcones and flavanones from hops, have been studied as potential anti-neoplastic agents 
(115,120).
We initiated this project with the goal of investigating the potential cancer 
preventive properties of the various grain extracts. We opted for a general study of the 
nonpurified flavonoid fraction of the grains, instead of studying the properties of a single 
flavonoid present in them. In many previous studies the latter approach was taken to 
study the cancer chemopreventive mechanisms of flavonoids. Genistein from soy, 
resveratrol from grapes and quercetin are examples of polyphenols studied extensively in 
this way. We were interested in a method that would allow us to determine the 
chemopreventive potential of the grain extracts as a whole. This approach would also let 
us evaluate the need for further research in the single components of these extracts. One 
disadvantage of our method is that other compounds present in the extracts may also 
contribute to the effect observed. For example, the lack of COX-2 inhibition observed 
may be due to an opposite inducing effect of one or more components of the extracts. 
Isolation of different sub-fractions should be considered in future to evaluate this 
possibility.
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In conclusion, this project studied the potential cancer preventive properties of 
flavonoids from cereal grains and legumes. We explored the inhibition of the 
carcinogenic process at the initiation step, by inducing a Phase II detoxification enzyme, 
N Q O l, and at the promotion and progression step, by inhibiting COX-2. The results 
obtained in the NQOl studies suggest that the extracts from cereal grains and legumes 
have the potential to be cancer chemopreventive. Preliminary studies with the first set of 
extracts showed N QOl induction with most of the extracts. In experiments conducted 
with the second set of extracts, only spring red wheat, winter wheat, wild rice and lentils 
induced N Q O l activity. The reduction in significance seen with the new extracts suggests 
that at some point in the new extraction method we removed an important fraction of the 
extracts. Identification of compounds in such fractions should be considered in future 
studies. Further research is needed to evaluate the polyphenolic concentration necessary 
to cause a significant NQO l induction. For that purpose, we will prepare new extracts 
starting with a larger quantity of each grain and prepare serial dilutions of the extracts.
Results from COX-2 immunoblotting failed to show a significant COX-2 
inhibition when cells were exposed to a Ix and lOx dilution of the second set of extracts. 
Preliminary work with the first set of extracts showed COX-2 inhibition with the extracts 
of oats and rye, suggesting that compounds present in the first set of extracts may be lost 
in the filtration of the second set of extracts. Collection of the aqueous and lipid fractions 
of the extracts should also be considered in the future.
In future work, we will focus on the fractionation of the grain extracts and the 
isolation of the different components. We will also study the chemopreventive effects of 
the grain extracts in vivo, using an animal model susceptible to tumors. The number and
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size of the tumors in the animals fed with diets fortified with the various extracts will be 
used as a measure of cancer protection. This would allow us to study the efficacy of grain 
extract fractions in protecting against cancer when administered through the diet.
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